Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances.
Treatment of metastatic differentiated thyroid cancer is first based on the use of radioiodine and thyrotropin-suppressive thyroid hormone treatment. The recent availability of molecular-targeted therapies has lead to reconsideration of the treatment strategy in differentiated thyroid cancer patients with distant metastases who are resistant to radioiodine therapy. In those with progressive disease, treatment with kinase inhibitors should be offered preferably in the context of a prospective trial.
Schlumberger
Martin
M
Department of Nuclear Medicine and Endocrine Oncology, Referral Center for Refractory Thyroid Tumors, Institut National du Cancer, Institut Gustave Roussy , Villejuif, France. schlumbg@igr.fr
Sherman
Steven I
SI
D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000235:genetics; D002986:Clinical Trials as Topic; D018450:Disease Progression; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D008207:Lymphatic Metastasis; D020935:MAP Kinase Signaling System / Q000187:drug effects; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D013972:Thyrotropin / Q000037:antagonists & inhibitors; D013974:Thyroxine / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
D007457:Iodine Radioisotopes; D013972:Thyrotropin; D013974:Thyroxine